Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC Using Diffusion Weighted and Dynamic Contrast-Enhanced MRI
The purpose of this study was to determine if parameters derived from diffusion-weighted (DW-) and dynamic contrast-enhanced (DCE-) magnetic resonance imaging (MRI) can help to assess early response to peptide receptor radionuclide therapy (PRRT) with 90Y-DOTATOC in neuroendocrine hepatic metastases...
Main Authors: | Thomas Weikert, Ole Christopher Maas, Tanja Haas, Markus Klarhöfer, Jens Bremerich, Flavio Forrer, Alexander Walter Sauter, Gregor Sommer |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi-Wiley
2019-01-01
|
Series: | Contrast Media & Molecular Imaging |
Online Access: | http://dx.doi.org/10.1155/2019/1517208 |
Similar Items
-
Biokinetic and dosimetry of 90y-dotatoc therapy for neuroendocrine tumours
by: Krstić Dragana, et al.
Published: (2017-01-01) -
Calculation of absorbed dose due to the 90Y-DOTATOC peptide receptor radionuclide therapy by MCNP5/X
by: Jeremić Marija Ž., et al.
Published: (2018-01-01) -
Gastroenteropancreatic Neuroendocrine Tumors: Standardizing Therapy Monitoring with Ga-DOTATOC PET/CT Using the Example of Somatostatin Receptor Radionuclide Therapy
by: Wolfgang Luboldt, et al.
Published: (2010-11-01) -
Selective intraarterial radionuclide therapy with yttrium-90 (Y-90) microspheres for hepatic neuroendocrine metastases: Initial experience at a single center
by: Arslan Nuri, et al.
Published: (2011-01-01) -
The Dependence of Renal <sup>68</sup>Ga[Ga]-DOTATOC Uptake on Kidney Function and Its Relevance for Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu[Lu]-DOTATOC
by: Falk Gühne, et al.
Published: (2021-07-01)